- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
- Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
- Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
- Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
- Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
- Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
- Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
- Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
- Vaxxinity to Present at Upcoming November Medical and Investor Conferences
- Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
On Thursday, Vaxxinity Inc (VAXX:NMQ) closed at 0.4648, 18.84% above the 52 week low of 0.3911 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.4216 |
---|---|
High | 0.50 |
Low | 0.42 |
Bid | 0.45 |
Offer | 0.4624 |
Previous close | 0.418 |
Average volume | 432.24k |
---|---|
Shares outstanding | 126.75m |
Free float | 55.39m |
P/E (TTM) | -- |
Market cap | 52.98m USD |
EPS (TTM) | -0.4499 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼